Ardelyx Inc (ARDX)

[Cosa]

Good luck bro! Market cap is sitting at $2B which is a little heavy for the amount of current revs. But they did PR earlier this year that they believe the potential revenue for Ibsrela is $1B. If this does play out, then $2B is peanuts and the SP could go much much higher. Especially if Xphozah starts taking off in the next year or two. But the company is growing so the story is not written yet...


The company forecast IBSRELA to bring in more than $1 billion in annual net product sales at its peak, according to its press release on Monday. It also said it expects to generate $2.5 million in product sales of XPHOZAH in the first quarter of commercialization of the treatment designed to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.